98%
921
2 minutes
20
Hypertrophic cardiomyopathy (HCM) is characterized by myocardial hypertrophy and can lead to significant complications including left ventricular outflow tract obstruction (LVOTO) and myocardial ischemia. Microvascular dysfunction (MVD) is a less recognized but crucial cause of myocardial ischemia in HCM, contributing to myocardial injury in the absence of obstructive coronary artery disease. We presented a case of a 48-year-old male with retrosternal chest tightness radiating to the left arm for 3 h. Electrocardiography revealed left ventricular (LV) hypertrophy with ST-segment depression and T wave inversion. High-sensitivity troponin T levels were elevated. Echocardiography showed marked LV wall thickness, predominantly at the basal septum, with systolic anterior motion of anterior mitral valve leaflet causing LVOTO. Adenosine stress cardiac magnetic resonance imaging demonstrated faint patchy scars in the hypertrophied ventricular septum and significant stress-induced perfusion defects beyond the area of myocardial scarring. Coronary angiography showed normal epicardial arteries, suggesting MVD as the underlying cause of ischemia. The patient was treated with nebivolol and verapamil, leading to symptom relief and a reduction in the pressure gradient of LVOTO at follow-up. This case highlights the role of MVD in causing myocardial ischemia in patients with HCM. Effective management of HCM with MVD includes pharmacological therapy to alleviate outflow obstruction and improve myocardial perfusion. Comprehensive diagnostic and treatment approaches are essential for optimizing outcomes in patients with this complex condition.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786631 | PMC |
http://dx.doi.org/10.1016/j.radcr.2024.12.048 | DOI Listing |
JAMA Netw Open
September 2025
Division of Cardiology, Duke University Hospital, Durham, North Carolina.
Importance: Previous data suggest that the time changes associated with daylight savings time (DST) may be associated with an increased incidence of acute myocardial infarction (AMI).
Objective: To determine whether the incidence of patients presenting with AMI is greater during the weeks during or after DST and compare the in-hospital clinical events between the week before DST and after DST.
Design, Setting, And Participants: This cross-sectional study examined patients enrolled in the Chest Pain MI Registry from 2013 to 2022.
Cardiovasc Interv Ther
September 2025
Division of Cardiovascular Medicine, Toyohashi Heart Center, Aichi, Japan.
The outcome of percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) is still controversial for patients with left main coronary artery (LMCA) disease. This multicenter cohort study aimed to evaluate the clinical outcomes of LMCA disease patients who underwent PCI or CABG. We reviewed 875 consecutive patients diagnosed with LMCA disease between January 2009 and December 2020 who underwent coronary revascularization by PCI (n = 404) or CABG (n = 471).
View Article and Find Full Text PDFJ Thromb Thrombolysis
September 2025
Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt.
In this review, we aimed to evaluate Sonothrombolysis when combined with primary percutaneous coronary intervention (pPCI) in STEMI patients with regard to improving cardiac function and clinical outcomes. This study primarily assesses short-term efficacy outcomes, while long-term impacts, such as mortality, were not evaluated. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) to identify eligible studies reported up to November 2024.
View Article and Find Full Text PDFEur Heart J
September 2025
Cardiovascular and Genomics Research Institute, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Myocardial infarction (MI) is defined pathologically as myocardial cell death resulting from prolonged ischaemia. The clinical definition of this pathological process relies on clinical evidence of myocardial ischaemia and biomarker evidence of myocardial cell death. Cardiac troponins are the standard clinical biomarker for assessing cardiac cell death.
View Article and Find Full Text PDFBackground: The lncRNA-miRNA-mRNA regulatory network is recognized for its significant role in cardiovascular diseases, yet its involvement in in-stent restenosis (ISR) remains unexplored. Our study aimed to investigate how this regulatory network influences ISR occurrence and development by modulating inflammation and immunity.
Methods: By utilizing data extracted from the Gene Expression Omnibus (GEO) database, we constructed the lncRNA-miRNA-mRNA regulatory network specific to ISR.